Search
Lamivudine
go.drugbank.com/drugs/DB00709ApprovedInvestigationalA reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. … It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Mixtures: LAMIHOPE-T (LAMIVUDINE 300MG AND TENOFOVIR DISOPROXIL FUMARATE 300MG FILM-COATED TABLETS), TENOLAM-ECategories: Antivirals used in combination for the treatment of HIV infectionsCannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalIn contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body … Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsProducts: leafPro CBDmed Oil T-FS QD 5%, leafPro CBDmed Oil T-FS QD 20%Doxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. … [L5971] However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.[L5974]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsProducts: DOXEPIN DURA T 50MG, DOXEPIN DURA T 100MGRotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalLike other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. … In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsTiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. … [A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Categories: Agents to Treat Airway DiseaseProducts: BROMURO DE TIOTROPIO 18 µG CÁPSULA, TIOSYNT BROMURO DE TIOTROPIO 18 MCG /POLVO PARA INHALACIONBendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawnthe denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863. … a small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation.
Buspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalBelonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates … Buspirone was first approved in 1986 by the FDA [A181751] and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Dopamine D2 Receptor AntagonistsEnalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalEnalaprilat is the active metabolite of the orally available pro-drug, [enalapril]. … Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth.
Categories: Agents Acting on the Renin-Angiotensin SystemCefpodoxime
go.drugbank.com/drugs/DB01416ApprovedInvestigationalVet approvedCommonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawn[A32080] Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.